None listed
Conditions
Brief summary
This randomised controlled trial compares the safety and efficacy of using supplemental Insulin Aspart (Novorapid) vs Actrapid to maintain tight glycaemic control in hospitalised patients with diabetes.
Interventions
The aim is to achieve tight glycaemic control with supplemental subcutaneous insulin, either Novorapid, or Actrapid. For subjects randomised to Novorapid, they will receive supplemental Novorapid if their glucose level is >8 mmol/L at a standard testing time (before meals/after meals/2200), in accordance with an algorithm which takes into consideration the subject's weight, glucose level and time of day. Subjects randomised to Actrapid will be administered supplemental insulin if their glucose l
The aim is to achieve tight glycaemic control with supplemental subcutaneous insulin, either Novorapid, or Actrapid. For subjects randomised to Novorapid, they will receive supplemental Novorapid if their glucose level is >8 mmol/L at a standard testing time (before meals/after meals/2200), in accordance with an algorithm which takes into consideration the subject's weight, glucose level and time of day. Subjects randomised to Actrapid will be administered supplemental insulin if their glucose level is >10 mmol/L, in accordance with a similar algorithm. The intervention will continue until discharge, or the occurence of an event which mandates withdrawal (eg becomes nil by mouth, insulin infusion commenced). This is a hospital based intervention only.
Sponsors
NW Cheung
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
diabetes on oral agents or insulin
Exclusion criteria
pregnant ketoacidosis nil by mouth
Outcome results
None listed